Penatalaksanaan Paripurna Sindrom Sjögren

Riris Asti Respati; Windy Keumala Budianti

doi:10.36452/jkdoktmeditek.v27i2.2034

Authors

Riris Asti Respati Departemen Dermatologi dan Venereologi Fakultas Kedokteran Universitas Indonesia (FK UI)/RSPN dr. Cipto Mangunkusumo, Jakarta, Indonesia
Windy Keumala Budianti Departemen Dermatologi dan Venereologi, Fakultas Kedokteran, Universitas Indonesia/RSUPN dr. Cipto Mangunkusumo, Jakarta, Indonesia

DOI:

https://doi.org/10.36452/jkdoktmeditek.v27i2.2034

Keywords:

manifestasi kulit, sindrom sika, sindrom sjögren, tata laksana

Abstract

Sindrom Sjögren (SS) adalah penyakit autoimun yang ditandai dengan infiltrasi limfosit pada kelenjar eksokrin dan menyebabkan sindrom sika. Patogenesis SS masih belum diketahui sepenuhnya namun diduga terdapat kerusakan epitel kelenjar eksokrin karena peningkatan respons sel B dan sel T terhadap autoantigen Ro (SS-A) dan La (SS-B). Manifestasi klinis SS dibedakan menjadi glandular dan ekstraglandular. Tatalaksana SS terdiri atas lokal dan sistemik yang bertujuan untuk meningkatkan kualitas hidup dengan mengurangi gejala kekeringan. Tinjauan Pustaka dibuat berdasarkan rangkuman dari berbagai artikel asli, baik laporan hasil penelitian atau sumber kepustakaan lain contohnya buku teks, jurnal, dan lain-lain. Tujuan tinjauan pustaka ini adalah untuk memberikan pengetahuan tata laksana terkini pada SS.

References

Illei G, Danielides S. Sjögren’s syndrome. In: Goldsmith LA, Kats SI, Giichrest BA, Paller AS, Leffel DJ, Wolff K. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill. 2012: p.1976-85.

Qin B, Wang J, Yang Z, Yang M, Ma N, Huang F, et al. Epidemiology of primary sjögren’s syndrome: a systematic review and meta-analysis. Ann Rheum Dis. 2014;0:1–7.

Stefanski AL, Tomiak C, Pleyer U, Dietrich T, Burmester GR, Dörner T. The diagnosis and treatment of sjögren’s syndrome. Dtsch Arztebl Int. 2017;114:354–61.

Both T, Dalm VA, Hagen PM, Daele PL. Reviewing primary sjögren’s syndrome- beyond the dryness-From pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14(3):191-200.

Vivino FB, Carsons SE, Foulks G, Daniels TE, Parke A, Brennan MT, et al. New treatment guidelines for sjögren’s disease. Rheum Dis Clin N Am. 2016;42:531–51.

Nair JJ, Singh TP. Sjögren's syndrome: review of the aetiology, pathophysiology & potential therapeutic interventions. J Clin Exp Dent. 2017;9(4):e584-9.

Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, et al. The 2011 Oxford CEBM levels of evidence (introductory document). Oxford Centre for Evidence-Based Medicine. [cited 2021 Jan 2]. Available from: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/ocebm-levels-of-evidence

Generali E, Costanzo A, Mainetti C, Selmi C. Cutaneous and mucosal manifestations of sjögren’s syndrome. Clinic Rev Allerg Immunol. 2017;53:357–70.

Priori R, Minniti A, Picarelli G, Valesini G. Extraglandular involvement in sjögren’s syndrome. In : Roccatello D, Emmi L. Connective tissue disease. Cham: Springer. 2016. p.319-32

Vivino FB. Sjögren’s syndrome-clinical aspects. Clin Immunol. 2017;182:48-54.

Baldhini C, Bernacchi E, Talarico R, Bombardieri S. Skin manifestations and sjögren’s syndrome. In: Matucci-Cerinic M, Furst D, Fiorentino D. Skin manifestations in rheumatic disease. 1st ed. New York: Springer-Verlag. 2014: p.207–17

Ramos-Casals M, Brito-Zero P, Seror R, Bootsma H, Bowman SJ, Dorner T. Characterization of systemic disease in primary sjögren’s syndrome EULAR-SS task force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatol. 2015;54:2230-8.

Yuliasih. Sindrom Sjögren. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata M, Setiyahadi B, Syam AF,editor. Buku ajar ilmu penyakit dalam. 6th ed. Jakarta: Interna publishing. 2016: p.2514-8

Shiboski CH, Shiboski SC, Seror R, Criswell LA, Labetoulle M, Lietman TM. 2016 ACR-EULAR classification criteria for primary sjögren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts. Arthritis Rheumatol. 2017;69(1):35-45.

Billings M, Amin Hadavand M, Alevizos I. Comparative analysis of the 2016 ACR-EULAR and the 2002 AECG classification criteria for sjögren's syndrome: findings from the NIH cohort. Oral Dis. 2018;24(1-2):184-190

Fox RI, Fox CM. Therapy of oral and cutaneous dryness manifestations in sjögren’s syndrome. In : Ramos-Casals M, Stone JH, Moutsopoulos HM. Sjögren syndrome diagnosis and therapeutics. London: Springer. 2012:p517-45

Xin W, Leung KC, Lo EC, Mok MY, Leung MH. A randomized, double-blind, placebocontrolled clinical trial of fluoride varnish in preventing dental caries of sjögren’s syndrome patients. BMC Oral Health. 2016;16(1):102.

American Dental Association Council on Scientific Affairs. Professionally applied topical fluoride evidence-based clinical recommendations. JADA. 2016;137:1151-9.

Brito‐Zerón P, Baldini C, Bootsma H, Bowman SJ, Jonsson R, Mariette X, et al. Sjögren syndrome. Nat Rev Dis Primers. 2016;2:16047.

Del Papa N, Vitali C. Management of primary sjögren’s syndrome-recent developments and new classification criteria. Ther Adv Musculoskelet Dis. 2018;10(2):39-54.

Qiu W, Liu Z, Ao M, Li X, Wang W. Punctal plugs versus artificial tears for treating primary sjögren's syndrome with keratoconjunctivitis SICCA: a comparative observation of their effects on visual function. Rheumatol Int. 2013;33(10):2543-8.

Yoshida A, Devecı H, Kobak S. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with sjögren’s syndrome. Int Ophthalmol. 2014;34(5):1043-8.

Liu Y, Hirayama M, Cui X, Connell S, Kawakita T, Tsubota K. Effectiveness of autologous serum eye drops combined with punctal plugs for the treatment of sjögren syndrome-related dry eye. Cornea. 2015;34(10):1214-20.

Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, Bosch X, Tzioufas AG.Topical and systemic medications for the treatment of primary sjögren's syndrome. Nat Rev Rheumatol. 2012;8(7):399-411.

Cifuentes M, Del Barrio-Díaz P, Vera-Kellet C. Pilocarpine and artificial saliva for the treatment of xerostomia and xerophthalmia in sjögren syndrome: a double‐blind randomized controlled trial. Br J Dermatol. 2018;179(5):1056-61.

Chen X, Wu H, Wei W. Advances in the diagnosis and treatment of sjögren’s syndrome. Clin Rheumatol. 2018;37(7):1743-9.

Wang SQ, Zhang LW, Wei P, Hua H. Is hydroxychloroquine effective in treating primary sjögren's syndrome: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2017;18(1):186.

Garcia-Carrasco M, Jimenez-Herrera EA, Galvez-Romero JL, Lara LV, Mendoza-Pinto C, Morales I, et al. Vitamin D and sjögren syndrome. Autoimmun Rev. 2017;16(6):587-93.

Erten S, Sahin A, Altunoglu A, Gemciouglu E, Koca C. Comparison of plasma vitamin D levels in patiens with sjögren’s dyndrome and healthy subjects. Int J Rheum Dis. 2015;18(1):70-5.

Bowman SJ, Everett CC, O'Dwyer JL, Emery P, Pitzalis C, Ng WF, Pease CT. Randomized controlled trial of Rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome. Arthritis Rheumatol. 2017 Jul;69(7):1440-1450

Gottenberg JE, Cinquetti G, Larroche C, Combe B, Hachulla E, Meyer O. Efficacy of rituximab in systemic manifestations of primary sjögren's syndrome: results in 78 patients of the autoimmune and Rituximab registry. Ann Rheum Dis. 2013 Jun;72(6):1026-31.

Tsuboi H, Matsumoto I, Hagiwara S, Hirota T, Takahashi H, Ebe H, et al. Efficacy and safety of abatacept for patients with sjögren's syndrome associated with rheumatoid arthritis: rheumatoid arthritis with orencia trial toward sjögren's syndrome endocrinopathy (ROSE) trial-an open-label, one-year, prospective study-Interim analysis of 32 patients for 24 weeks. Mod Rheumatol. 2015;25(2):187-93.

Seror R, Theander E, Bootsma H, Bowman SJ, Tzioufas A, Gottenberg JE, et al. Outcome measures for primary sjögren syndrome: a comprehensive review. J Autoimmun. 2014;51:51-6.